Selexis CHO Cells in Suspension-1

In the News

Read more about Selexis partnerships, technology and people featured in key media outlets.


November 9, 2021

Contract Pharma

Orphan Drug Development Trends by Dirk Lange, CEO of Selexis SA & President and CEO of KBI Biopharma


July 13, 2021

BioProcess International

Selexis and KBI to advance Immatics program toward IND by Millie Nelson


June 2, 2021

Contract Pharma

Selexis SA Appoints Hoffmann-Hecht CBO by Kristin Brooks


March 23, 2021

The Science Advisory Board

Selexis, Tallac to advance novel immunotherapies by The Science Advisory Board Staff


March 18, 2021


Other news to note for March 18, 2021 by BioWorld Staff


March 19, 2021

The Pharma Letter

Selexis signs license deal with SpyBiotech on HCMV vaccine program by The Pharma Letter Staff


March 16, 2021

Contract Pharma

Selexis, Pandion Enter Antibody Service Agreement by Kristin Brooks


March 9, 2021

Drug Discovery News

An agreement to advance BITR2101 by Mel J. Yeates



May 19, 2020

Contract Pharma

Selexis Makes Scientific and Operational Promotions by Contract Pharma Staff


February 11, 2020

Genetic Engineering & Biotechnology News

Selexis Cell Line Development Strategies by John Morrow Jr., Ph.D.



September 21, 2019

The Center for Biosimilars

First Dornase Alfa Biosimilar Approved and Launched in Russia by The Centers for Biosimilars Staff


April 11, 2019

Selexis’ biologic platform generates first-ever approved Soliris biosimilar by Maggie Lynch


April 11, 2019 

BioProcess International

World’s first Soliris biosimilar launched in Russia by Dan Stanton


January 14, 2019

BioProcess International

Selexis and Agenus expand immune-oncology cell line deal by BPI Staff



December 27, 2018 

BioProcess International

TeneoBio expands cell banking deal with Selexis by Dan Stanton


October 9, 2018

BioProcess International

Hoba (cell) banks on Selexis to advance neuropathic pain program by Dan Stanton


July 11, 2018

Selexis and Symphogen Expand Partnership to Process two mAbs by Ben Hargreaves


April 19, 2018

Selexis Says $2M Investment Will Speed Up Cell Bank Delivery Time by Flora Southey


February 28, 2018


Xencor extends collaboration with Selexis to advance bispecific antibody programs by Angus Liu



November 1, 2017

Genetic Engineering & Biotechnology News

Weighing Protein Expression Levels with Cell Growth by Angelo DePalma, Ph.D.


June 27, 2017 

BioProcess International

Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins by BPI Contributor


May 8, 2017

Selexis’ Swiss investment in mammalian cell lines by Flora Southey


February 21, 2017

Sanofi hires Selexis SA for three cell line development deals by Gareth Macdonald



October 10, 2016

Contract Pharma

Cell Line Development Trends: How CHO cell line development technologies are improving biologics development from early phase to IND by Igor Fisch, Ph.D.


October 7, 2016

BioProcess International

BioProcess International Announces Winners of the 2016 BioProcess International Awards by BPI Staff


September 12, 2016

Selexis to triple cell line capacity on back of increased demand by Dan Stanton


April 18, 2016 

BioProcess International

Cancer Immunotherapies: Fulfilling the Promise of Protein and Cell Therapies by Angelo DePalma


April 15, 2016

Genetic Engineering & Biotechnology News

GEN Roundup: How to Improve Cell-Line Productivity by GEN Staff Writer



May 11, 2015

Genetic Engineering & Biotechnology News

Ligand Buys Another 15 Biologics Programs from Selexis for $4M by GEN Staff Writer